Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
J Hum Hypertens ; 35(7): 588-597, 2021 07.
Article in English | MEDLINE | ID: mdl-32839534

ABSTRACT

The aim of this study was to investigate the possible relationship between worse clinical outcomes and the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in hospitalized COVID-19 patients. A total of 247 adult patients (154 males, 93 females; mean age: 51.3 ± 14.2 years) hospitalized for COVID-19 as confirmed by polymerase chain reaction (PCR) were retrospectively reviewed. Demographic and clinical characteristics and laboratory parameters were analyzed using various statistical modeling. Primary outcomes were defined as the need for intensive care unit (ICU), mechanical ventilation, or occurrence of death. Of the patients, 48 were treated in the ICU with a high flow oxygen/noninvasive mechanical ventilation (NIMV, n = 12) or mechanical ventilation (n = 36). Median length of ICU stay was 13 (range, 7-18) days. Mortality was seen in four of the ICU patients. Other patients were followed in the COVID-19 services for a median of 7 days. There was no significant correlation between the primary outcomes and use of ACEIs/ARBs (frequentist OR = 0.82, 95% confidence interval (CI) 0.29-2.34, p = 0.715 and Bayesian posterior median OR = 0.80, 95% CI 0.31-2.02) and presence of hypertension (frequentist OR = 1.23, 95% CI 0.52-2.92, p = 0.631 and Bayesian posterior median OR = 1.25, 95% CI 0.58-2.60). Neutrophil-to-lymphocyte ratio (NLR) and D-dimer levels were strongly associated with primary outcomes. In conclusion, the presence of hypertension and use of ACEIs/ARBs were not significantly associated with poor primary clinical outcomes; however, NLR and D-dimer levels were strong predictors of clinical worsening.


Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , COVID-19/diagnosis , Hypertension/drug therapy , SARS-CoV-2/isolation & purification , Adult , Aged , Aldosterone/adverse effects , Aldosterone/therapeutic use , Angiotensin Receptor Antagonists/adverse effects , Angiotensin-Converting Enzyme Inhibitors/adverse effects , COVID-19 Nucleic Acid Testing , Female , Fibrin Fibrinogen Degradation Products/analysis , Humans , Hypertension/diagnosis , Lymphocytes , Male , Middle Aged , Neutrophils , Polymerase Chain Reaction , Renin-Angiotensin System , Retrospective Studies , SARS-CoV-2/genetics
2.
Ren Fail ; 37(6): 951-6, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26030798

ABSTRACT

INTRODUCTION: Left ventricular hypertrophy (LVH) is a significant risk factor for cardiovascular complications in hemodialysis (HD) patients. Hypervolemia has been accepted as an independent risk factor for progressive LVH in HD patients. Additionally, high FGF23 levels have been a significant predictor of cardiovascular mortality and morbidity in chronic kidney disease and HD patients. The aim of our study is to investigate the correlation among LVH, interdialytic volume increase and FGF-23 in the patients on a chronic hemodialysis program. DESIGN AND METHODS: A total of 97 chronic hemodialysis patients (64.43 ± 11.28 years old, M/F:47/50) were included in the study. Human FGF-23 ELISA kit was used for FGF-23 analysis of predialysis blood samples. Echocardiographic evaluation was performed in all of the patients after dialysis. Left Ventricular Mass Index (LVMI) was calculated by using the Devereux Formula. We collected the following data: LVMI, FGF-23 levels, interdialytic fluid gain, blood pressure changes, and the other biochemical and clinical parameters. RESULTS: Mean LVMI of the patients was 184.41 ± 48.62 g/m(2). LVMI of the patients with daily urine output > 250 mL was found significantly lower. Statistically significant positive correlation was found between predialysis systolic blood pressure, predialysis diastolic blood pressure, predialysis mean arterial blood pressure and LVMI measurements (p < 0.01). Mean interdialytic volume excess was correlated with LVMI measurements of the patients (r = 0.459; p < 0.01). Increased FGF-23 levels (159.79 ± 134.99 ng/L) predicted increased LVMI measurements of the patients (r = 0.322; p < 0.01). In addition, FGF-23 levels were also increased as the interdialytic fluid volume increased (r = 0.326; p < 0.05). A positive correlation was also found between FGF-23 levels and interventricular septum thickness (r = 0.238; p < 0.05). Predialysis mean arterial blood pressure, predialysis volume overload and presence of diabetes were determined to be independent risk factors on LVMI on multivariate regression analysis. CONCLUSION: Our study showed that interdialytic volume overload increased both LVMI and FGF-23 values. We can consider that interdialytic volume control exerts positive effects on increased FGF-23 levels which predict the negative cardiovascular outcomes.


Subject(s)
Fibroblast Growth Factors/blood , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/mortality , Kidney Failure, Chronic/therapy , Renal Dialysis/adverse effects , Water-Electrolyte Imbalance/complications , Adult , Aged , Biomarkers/blood , Cohort Studies , Disease Progression , Echocardiography, Doppler/methods , Female , Fibroblast Growth Factor-23 , Hemodialysis Units, Hospital , Humans , Hypertrophy, Left Ventricular/blood , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/mortality , Linear Models , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prospective Studies , Renal Dialysis/methods , Risk Assessment , Survival Rate , Treatment Outcome , Turkey , Water-Electrolyte Imbalance/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...